London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
what is this rns mean
Ergomed continuing with revamp of the BOD with another ex-Chiltern appointment who now make up just under half of the BOD.
Also 2nd RNS (total voting rights) suggests some share options have been exercised with total shares in issue slightly increasing by approx. 36k to 47275317.
Whats with the stock price dropping???
Ergomed a stock that just keeps on giving - my best buy for 2019. Let's hope for a strong finish to the year.
For those interested in other growing Pharma stocks, big news this week from Open Orphan! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.
This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.
This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.
CEO Cathal Friel summaries the significance of the agreement in 2 minute video below. https://www.brrmedia.co.uk/broadcasts-embed/5dc99abe34a3cf1389e844e9/?open-orphan-rns&popup=true
Some very large trades going through again today - £3m and £4m at 9.22, 2 x £1m at 9.30, another £1m at 9.44 all at 375p and again presumably part of the same transaction.
Yep - big trades going through @ 355p - in total over 1m shares and over £3.5m at this price. Assume they're all part of the same transaction.
Some HUGE trades went thru
100K
250K x 2
Yes they were "sells" but someone bought them
RNS tomorrow??? Were these insider transactions?????
I’m from the states. What are these two Price Monitoring Extn RNS
Good. Bad?
For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.
Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. -
"When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million.
That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."
https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)
For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph"
Below is link to a letter sent by Cel-Sci's CEO to all of their shareholders today. Have to say, it seems to be a highly unusual approach. Hope the trial is a success, otherwise I'm not sure that letter is going to age well.
https://www.businesswire.com/news/home/20191024005515/en/CEL-SCI-Corporation-Issues-Letter-Shareholders/
2 large transactions, each over 100K today.
Keep an eye out for a RNS tomorrow
Co-development company Cel-Sci announced this afternoon that the IDMC have reviewed unblinded data from their ongoing phase III head and neck cancer trial and recommended the trial continues until the appropriate number of events has occurred. The endpoint of the trial is when 298 events (deaths) have been reached.
https://www.businesswire.com/news/home/20191015005305/en/CEL-SCI-Reports-Data-Review-Independent-Data-Monitoring
Barfield has a reputation of acquisitions and then selling companies. He will probably grow the company for the next 3 years before it is then sold.
Great call. What makes you think this is going to be taken over...? Dont normally see so much turnover prior to a takeover
Being setup for a takeover bid. Will see a rise here on Monday.
Strong interim results announced today:-
Revenue up 37%
Backlog up 27% to £118m
Major new contracts, including 1400 patient phase III
cash generating, profit making and debt free!
Interview with CFO, Richard Barfield below
https://www.youtube.com/watch?v=3n8mhLCwtBI
Thoughts on the COO leaving???
While the volume has been light the recent few weeks. Any sense we the down turn from the Highs?
Looks like interim results out on the 25th
Thanks for the info.
No, others may know better but I don't think UK companies have to notify the market of the expected publication date of interim results. Not sure whether it's compulsory but most issue a notification of the date for the annual results.
Looks like the Interim Results for 2019 will be out in 3 weeks or so. Are UK companies required to notify the public of the exact date or will it just be a "surprise" when it comes out?
They meet every 6 mos. we think they report about 2 weeks after meeting. Thus, no later thanks early oct.
sushifishman,
Does the trial have 6 monthly planned IDMC reviews then? How long do they typically take to report their decision?
Cherio from the States
Nice to see a new 52 week high.
Multikine (Cel Sci) will have it’s 6 month checkup by the IDMC in a few weeks.
It will make or break this trial imo
More details on what the idmc does here: KillCVMShorts.com/idmc
Courtesy of sushifishman, Cel-Sci published an updated fact sheet on 9th August which shows that they are still waiting for 298 events (deaths) in their ongoing Multikine phase III trial.
The head & neck cancer trial completed recruitment with its 928th patient in September 2016 and is continuing to monitor survival. The trial will end when 298 events have occurred and that was expected to happen in 2018 so the fact that they haven't yet reached that threshold may be promising.
https://cel-sci.com/wp-content/uploads/2019/08/CVM_FactSheet_website_080919.pdf